Amplification and Deletion of Topoisomerase IIα Associate with ErbB-2 Amplification and Affect Sensitivity to Topoisomerase II Inhibitor Doxorubicin in Breast Cancer

This publication has 62 references indexed in Scilit:

• Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
  Oncogene, 1999
• Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation
  The EMBO Journal, 1998
• Genetic Aberrations in Hypodiploid Breast Cancer: Frequent Loss of Chromosome 4 and Amplification of Cyclin D1 Oncogene
  The American Journal of Pathology, 1998
• The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells
  Oncogene, 1997
• Cell Cycle–coupled Relocation of Types I and II Topoisomerases and Modulation of Catalytic Enzyme Activities
  The Journal of cell biology, 1997
• Antitopoisomerase drug action and resistance
  Published by Elsevier ,1996
• In vivo amplification of the androgen receptor gene and progression of human prostate cancer
  Nature Genetics, 1995
• Interphase cytogenetic analysis of erbB2 and topollα co‐amplification in invasive breast cancer and polysomy of chromosome 17 in ductal carcinoma in situ
  International Journal of Cancer, 1995
• Sublethal damage repair after fractionated irradiation in endometrial cancer cell lines tested with the 96-well plate clonogenic assay
  Zeitschrift für Krebsforschung und Klinische Onkologie, 1994
• Co-amplification of erbB2, topoisomerase II α and retinoic acid receptor α genes in breast cancer and allelic loss at topoisomerase I on chromosome 20
  European Journal Of Cancer, 1993